StimRouter Genicular NeuromoduLation for Chronic KnEe OsteoArthritic Pain Management
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Knee Pain
研究概览
简要总结
The goal of this study is to evaluate the use of StimRouter Neuromodulation System (StimRouter) in adult subjects with an established diagnosis of primary femorotibial osteoarthritis in the target knee (Kellgren-Lawrence ≥1) who have surgical contraindications to undergo a knee joint arthroplasty procedure. The main questions it aims to answer are:
- To assess the effect of the StimRouter Neuromodulation System to manage joint pain in patients with symptomatic OA of the knee who are surgically contraindicated to undergo a knee joint arthroplasty
- To assess the effect of StimRouter on joint stiffness, function and patient quality of life
Participants will have StimRouter leads implanted then clinic visits will be scheduled for follow-up at Week 2, Month 3 and Month 6 (End of Study (EOS) or Early Termination (ET)).
详细描述
This study will be a single-center, single-arm, open label pilot study evaluating the safety and efficacy of the StimRouter Neuromodulation System as a peripheral nerve stimulator targeting knee joint innervation of moderately to severely symptomatic subjects with OA of the knee who are non-eligible to undergo a joint arthroplasty at the target knee.
Up to 30 subjects will be enrolled and participate in the study. Clinic visits will be scheduled at Screening, Stimulation Trial Procedure, Trial Assessment Visit, Implant Procedure and Follow-up Week 2, Month 3 and Month 6 (End of Study (EOS) or Early Termination (ET)).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is at least 21 years of age at the time of giving informed consent
- •Radiographic disease Stage ≥ 1 in the target knee according to the Kellgren-Lawrence grading of knee OA
- •Knee joint arthroplasty procedure is contraindicated
- •Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
- •Subjects must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed
排除标准
- •Subject has undergone previous joint arthroplasty procedure (partial, total, patella-femoral) to the index knee
- •Unresolved effusion of the target knee clinically requiring aspiration within 12 weeks prior to Visit 1 (Baseline)
- •Treatment of the index knee with systemic or intra-articular corticosteroids (e.g., methylprednisolone) within 6 weeks prior to Visit 1 (Baseline)
- •Visco-supplementation (e.g., hyaluronic acid) in the index knee within 6 weeks prior to Visit 1 (Baseline)
- •Subject has an active systemic infection or an active local infection in or near the index knee joint, or has a previous history of joint infection.
- •Subject with bleeding disorders or active anticoagulation that cannot be stopped for a few days prior to the time of the surgical procedure.
- •Subject who has an active or existing skin disorder or irritation, which, in the opinion of the Investigator, precludes the use of skin gel electrodes.
- •Subjects has or plans to have a pacemaker, defibrillator, cochlear implant, and/or a sleep apnea implant.
- •Subject has or plans to have a Spinal Cord Stimulator (SCS), Peripheral Nerve field Stimulation system (PNfS), Dorsal Root Ganglion system (DRG), or implantable infusion pump.
- •Subject who currently requires or is likely to require Magnetic Resonance Imaging (MRI) within the MRI exclusion zone: the entire PNS lead must be at least 50 cm from the center of the MRI system's bore (the iso-center) and at least 16 cm outside of the MRI coil measured from the edge of the MRI coil.
- •Female subject who is pregnant or nursing or plans to become pregnant during the study. The effects of electrical stimulation on pregnancy are not known. Do not use electrical stimulation (including StimRouter) during pregnancy.
- •Any condition and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
- •Comorbid conditions that could affect pain assessment of the target knee, including, but not limited to, inflammatory rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus
结局指标
主要结局
Knee Pain
时间窗: The primary endpoint is at Month 3 post permanent implantation.
Change in pain from Baseline to Month 3 in knee health as assessed by the KOOS-12 questionnaire. The KOOS-12 questionnaire is a 12-item measure derived from the original 42 item Knee injury and Ostoearthritis Outcome Score (KOOS). KOOS-12 contains 4 KOOS Pain items, 4 KOOS Function (Activities of Daily Living and Sport/Recreation) items, and 4 KOOS Quality of Life (QOL) items.
次要结局
- Secondary Interventions(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Health-Related Quality of Life (HRQOL)(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Knee Pain(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Knee Health(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Pain Experience(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Forgotten Joint Score (FJS)(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Treatment Satisfaction Scores(The primary endpoint is at Month 3 post permanent implantation.)
- Treatment Expectation Scores(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Serious Adverse Events (SAEs)(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)
- Adverse Events (AEs)(Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.)